Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fulvestrant in advanced breast cancer failing aromatase inhibitors
NCT00272740Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Mar 2000
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of fulvestrant in breast cancer, sponsored by AstraZeneca. Primary endpoint: Clinical Benefit Rate. Started Mar 2000; status: completed.
02
Drugs
fulvestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00272740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00272740.